GLP-1 research compounds in Canada span several generations of incretin science, and choosing between GLP-1 research compounds is a common question in Canadian metabolic laboratories, and Semaglutide, Tirzepatide, and Retatrutide represent three generations of incretin science. Each compound targets metabolic pathways differently. This overview compares their mechanisms, receptor activity, and research profiles so investigators can select the right tool for their study design.
Semaglutide: The Single GLP-1 Agonist
Semaglutide is a single-target GLP-1 receptor agonist. It mimics the incretin hormone glucagon-like peptide-1, which regulates insulin signalling and appetite pathways. In research models, Semaglutide shows a long half-life of roughly seven days, driven by fatty-acid acylation that improves albumin binding. This makes it a well-characterised benchmark compound. Studies frequently use it as the reference point when evaluating newer multi-receptor molecules. Its established data set makes it a reliable starting point for laboratories new to incretin research.
Tirzepatide: Dual GIP and GLP-1 Activity
Tirzepatide adds a second target. It activates both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor. This dual mechanism produces stronger effects on glucose handling and body-weight endpoints in preclinical models than single-agonist compounds. Researchers studying combined incretin signalling often select Tirzepatide because it isolates the contribution of GIP activation. Its once-weekly profile also supports extended study protocols where dosing frequency matters.
Retatrutide: The Triple Agonist Frontier
Retatrutide represents the newest frontier. It is a triple agonist that engages GLP-1, GIP, and the glucagon receptor. The added glucagon activity is thought to influence energy expenditure and lipid metabolism, distinguishing it from dual and single agonists. As the most recently developed of the three, Retatrutide has a smaller but rapidly growing research literature. Laboratories investigating energy-expenditure pathways or next-generation metabolic mechanisms typically turn to this compound. You can explore all three in the GLP-1 & Weight Loss research category.
Choosing GLP-1 Research Compounds in Canada
Selection depends on the research question. A study benchmarking established incretin effects may favour Semaglutide for its deep data set. Work examining the added value of GIP activation points toward Tirzepatide. Projects exploring glucagon-driven energy expenditure suit Retatrutide. Receptor complexity increases from one to three targets across the series, and so does the novelty of the mechanism under study. Comparative work sometimes runs all three side by side to map dose-response differences.
Handling and Reconstitution Considerations
All three compounds ship as lyophilised powder and require reconstitution with bacteriostatic water before use in the laboratory. Proper cold storage preserves peptide integrity across each of these molecules. Consistent handling protocols allow reliable comparison between the single, dual, and triple agonists. Researchers can find these compounds and related supplies in the EhBuddy Peptides shop.
For broader background on the incretin biology behind these GLP-1 research compounds in Canada, see this overview of GLP-1 signaling.
All products sold at EhBuddy Peptides are for laboratory and scientific research purposes only and are not intended for human or veterinary administration. EhBuddy Peptides ships all orders from within Canada.
